Search

Fate Therapeutics Inc

Open

BrancheGesundheitswesen

2.56

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.46

Max

2.59

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.1M

-30M

Verkäufe

783K

2.1M

EPS

-0.25

Gewinnspanne

-1,448.559

Angestellte

161

EBITDA

-2.3M

-31M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+162.75% upside

Dividenden

By Acuity

Nächstes Ergebnis

12. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-29M

292M

Vorheriger Eröffnungskurs

2.56

Vorheriger Schlusskurs

2.56

Nachrichtenstimmung

By Acuity

12%

88%

13 / 340 Ranking in Healthcare

Fate Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 19:46 UTC

Fate Therapeutics Inc is trading higher amid broader market dynamics influenced by rising oil prices and geopolitical tensions, though no specific news was identified.

22. Aug. 2026, 00:02 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting broader market gains following recent pressures from rising crude oil prices and bond yields.

20. Aug. 2026, 20:06 UTC

Correlated Moves

Fate Therapeutics Inc is declining today, mirroring a broader market drop. The stock remains below its 20-day moving average and near its one-month low.

19. Aug. 2026, 19:26 UTC

Correlated Moves

Fate Therapeutics Inc shares are higher, supported by a significant rise in the ARK Genomic Revolution ETF during Wednesday's session.

14. Aug. 2026, 19:26 UTC

Event
Social Media
News

Fate Therapeutics has begun its Phase 2 RECLAIM-LN trial for FT819, targeting lupus nephritis. Shares are higher during Friday's session.

13. Aug. 2026, 23:36 UTC

Fate Therapeutics shares are higher in after-market hours, reflecting a recovery from earlier declines amid broader market optimism regarding the Federal Reserve's interest rate policy.

12. Aug. 2026, 21:02 UTC

Fate Therapeutics Inc. is gaining in after-market trading, rebounding from three consecutive sessions of declines. The price remains above the 20-day moving average.

7. Aug. 2026, 20:03 UTC

Fate Therapeutics shares are higher, reaching a session high amid rising U.S. Treasury yields and a weakening U.S. Dollar Index. No specific news identified.

6. Aug. 2026, 19:26 UTC

Correlated Moves

Fate Therapeutics Inc shares are lower today, reflecting broader market trends and a decline in the Russell 2000 Index amid ongoing inflation concerns.

5. Aug. 2026, 19:56 UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

4. Aug. 2026, 20:07 UTC

News
Correlated Moves

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

3. Aug. 2026, 23:01 UTC

News

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

29. Juli 2026, 19:19 UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

28. Juli 2026, 16:06 UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

27. Juli 2026, 21:02 UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

24. Juli 2026, 19:07 UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

23. Juli 2026, 21:11 UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

22. Juli 2026, 23:46 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

20. Juli 2026, 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Peer-Vergleich

Kursveränderung

Fate Therapeutics Inc Prognose

Kursziel

By TipRanks

162.75% Vorteil

12-Monats-Prognose

Durchschnitt 6.7 USD  162.75%

Hoch 8 USD

Tief 3.5 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fate Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

3

Halten

0

Sell

Stimmung

By Acuity

13 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat